177Lu-DOTATATE Therapy of Advanced Pancreatic Neuroendocrine Tumors Heavily Pretreated with Chemotherapy: Analysis of Outcome, Safety, and Their Determinants | Zendy

Katarzyna FrössBaron | Zendy; Ulrike Garske–Román | Zendy; Staffan Welin | Zendy; Donald Granberg | Zendy; Barbro Eriksson | Zendy; Tanweera Shaheena Khan | Zendy; Mattias Sandström | Zendy; Anders Sundin | Zendy

Open Access

<sup>177</sup>Lu-DOTATATE Therapy of Advanced Pancreatic Neuroendocrine Tumors Heavily Pretreated with Chemotherapy: Analysis of Outcome, Safety, and Their Determinants

Author(s) -

Katarzyna FrössBaron,

Ulrike Garske–Román,

Staffan Welin,

Donald Granberg,

Barbro Eriksson,

Tanweera Shaheena Khan,

Mattias Sandström,

Anders Sundin

Publication year - 2020

Publication title -

neuroendocrinology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.493

H-Index - 101

eISSN - 1423-0194

pISSN - 0028-3835

DOI - 10.1159/000506746

Subject(s) - radionuclide therapy , medicine , neuroendocrine tumors , chemotherapy , toxicity , bone marrow , gastroenterology , bone marrow suppression , oncology , urology

To retrospectively analyze toxicity, progression-free survival (PFS), overall survival (OS), and their determinants in patients with advanced pancreatic neuroendocrine tumors (PanNETs), previously pretreated with chemothe-r-apy, undergoing peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research